ProCE Banner Series

Targeting CD47 in MDS and AML: An Emerging New Immunotherapy Approach

Join us live or virtually for an expert-led satellite symposium taking place in Frankfurt, Germany. This symposium will be held as part of the European Hematology Association 2023 Hybrid Conference and will focus on emerging immunotherapeutic approaches targeting CD47 in AML and MDS. Experts will discuss the latest evidence, answer audience questions, discuss unanswered questions, and highlight key clinical trials. Please note: You must be registered for the EHA 2023 Conference to attend this symposium. You may register at: https://ehaweb.org/congress/eha2023-hybrid-congress/registration/

  AMA
Who Should Attend

This global educational program is intended for hematologists, medical oncologists, and other healthcare professionals who treat patients with MDS and AML.

All Events

Targeting CD47 in MDS and AML: An Emerging New Immunotherapy Approach

Past Events

June

10

2023

5:30 PM - 7:30 PM Central European Summer Time (CEST)

In-personVirtual

Topics

Targeting CD47 in MDS and AML: An Emerging New Immunotherapy Approach

Additional Info

There are no fees required to participate in this activity.

Americans With Disabilities Act 
Event staff will be glad to assist you with any special needs (eg, physical, dietary). Please contact meetings@clinicaloptions.com prior to the live event.

CME/CE Info

Goal Statement
The goal of this activity is to improve the knowledge and competence in the rationale for and use of CD47 targeting agents in the treatment of MDS and AML.

Target Audience
This global educational program is intended for hematologists, medical oncologists, and other healthcare professionals who treat patients with MDS and AML.

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Communicate to colleagues and patients the role of CD47 in evasion of an immune response to higher-risk MDS and AML and the mechanism of action of anti-CD47 agents
  • Differentiate the efficacy and safety profile of anti-CD47 agents from other classes of agents used to treat MDS and AML
  • Select patients that meet the inclusion criteria for enrollment on pivotal trials of anti-CD47 agents in MDS and AML
  • Plan treatment strategies for patients with MDS and AML that include anti-CD47 agents when they become available

Accreditation

Joint Accreditation Statement

 

 

 

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation
CCO designates this live activity material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Conflicts of Interest
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

Acknowledgement

Provided by Clinical Care Options, LLC.

This program has been supported by an independent educational grant from Gilead Sciences, Inc. 

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address:

 

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191